Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

Study Overview
=================
Brief Summary
-----------------
This is an open-label observational crossover trial to study the efficacy of a commercial dietary supplement and its effect on common symptoms of IBS (such as bloating, gas, heartburn, and other symptoms).

Detailed Description
-----------------
It is hypothesized that the dietary supplement marketed as Arrae Bloat will improve subjective wellbeing in trial participants. It is further hypothesized that a second dietary supplement marketed as Arrae Calm will support the effects of Arrae Bloat, while reducing stress, anxiety and panic and promoting restful sleep and easing tension in the body, which has previously been reported in customer feedback studies.

Official Title
-----------------
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

Conditions
-----------------
IBS - Irritable Bowel Syndrome, Anxiety

Intervention / Treatment
-----------------
* Dietary Supplement: Arrae bloat supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female over 18 years old Self-reported (undiagnosed) IBS symptoms, such as self-reported abdominal pain, gas production and bloating after meals, heartburn after meals Must be in good health (don't report any medical conditions asked in the screening questionnaire) Following a stable, consistent diet regimen Agree to refrain from any lifestyle changes that may affect their GI tract and IBS symptoms for the duration of the study May have self-reported sleep issues May have self-reported mild anxiety/depression May have self-reported occasional panic attacks Exclusion Criteria: Prior prescriptions for IBS Current IBS treatment (e.g. proton pump inhibitors, laxatives) Follow an extreme diet intervention Experienced severe weight loss in the past 3 months prior to study participation Antibiotic usage within 3 months prior of study participation Usage any medication or herbal remedies which can affect the GI tract Food intolerances/allergies Pineapple sensitivity/allergy Taking cortisol lowering prescription medication Has any of the following medical conditions: History of GI tract cancers Celiac disease / gluten intolerance GI bleeding Rectal bleeding Heme-positive stool Iron-deficiency anemia Systemic signs of infection Insomnia Moderate to severe depression/anxiety Moderate to severe panic attacks - Females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arrae Bloat supplement<br>The Bloat capsules are a blend of 5 herbs and a fruit-based digestive enzyme that target the cause for IBS symptoms. | Dietary Supplement: Arrae bloat supplement<br>* The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in IBS symptoms (bloating, heartburn and gas) | Survey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in IBS symptoms between baseline and study intervention period. | 4 weeks | 
| Reduction in anxiety symptoms | Survey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in anxiety symptoms between baseline and study intervention period. | 8 weeks |